UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes

Journal of clinical oncology, 2011-06, Vol.29 (18), p.2557-2564

2011

Volltextzugriff (PDF)

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors

Journal of hematology and oncology, 2016-03, Vol.9 (22), p.23-9, Article 23

2016

Volltextzugriff (PDF)

First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer

Investigational new drugs, 2021-10, Vol.39 (5), p.1348-1356

2021

Volltextzugriff (PDF)

A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies

Investigational new drugs, 2020-04, Vol.38 (2), p.445-456

2020

Volltextzugriff (PDF)

BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer

Clinical cancer research, 2016-10, Vol.22 (20), p.5058-5067

2016

Volltextzugriff (PDF)

Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors

Molecular cancer therapeutics, 2012-08, Vol.11 (8), p.1820-1828

2012

Volltextzugriff (PDF)

A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2013-01, Vol.71 (1), p.93-101

2013

Volltextzugriff (PDF)

A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors

Cancer chemotherapy and pharmacology, 2013-03, Vol.71 (3), p.565-573

2013

Volltextzugriff (PDF)

Stereoselective Preparation of N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3- (2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide, a Potent and Orally Active Dual Neurokinin NK1/NK2 Receptor Antagonist

Journal of medicinal chemistry, 2003-07, Vol.46 (16), p.3508-3513

2003

Volltextzugriff (PDF)

At Liberty to Die: The Battle for Death with Dignity in America

Ball, Howard

1, 2012

Volltextzugriff (PDF)

Sense and antisense: therapeutic potential of oligonucleotides and interference RNA in asthma and allergic disorders

Clinical reviews in allergy & immunology, 2004-12, Vol.27 (3), p.207-218

2004

Volltextzugriff (PDF)

Effect of P‐glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine

British journal of clinical pharmacology, 2000-09, Vol.50 (3), p.237-246

2000

Volltextzugriff (PDF)

The Supreme Court in the Intimate Lives of Americans: Birth, Sex, Marriage, Childrearing, and Death

Ball, Howard

1, 2002

Volltextzugriff (PDF)

Dual neurokinin NK1/NK2 antagonists : N-[(R, R)-(E)-1-arylmethyl-3-(2-oxo-azepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis( trifluoromethyl)benzamides and 3-[N'-3,5-bis(trifluoromethyl)benzoyl-N-arylmethyl-N'-methylhydrazino]-N-[(R)-2- oxo-azepan-3-yl]propionamides

Bioorganic & medicinal chemistry letters, 2001-12, Vol.11 (23), p.3081-3084

2001

Volltextzugriff (PDF)

Biphenyl derivatives as novel dual NK1/NK2-Receptor antagonists

Bioorganic & medicinal chemistry letters, 2002-08, Vol.12 (16), p.2065-2068

2002

Volltextzugriff (PDF)

Prevention of vascular nitroglycerin tolerance by inhibition of protein kinase C

British journal of pharmacology, 1996-09, Vol.119 (1), p.3-5

1996

Volltextzugriff (PDF)

Clinical potential of respirable antisense oligonucleotides (RASONs) in asthma

American journal of pharmacogenomics, 2003, Vol.3 (2), p.97-106

2003

Volltextzugriff (PDF)

Simultaneous LV and RV volumes by conductance catheter: effects of lung insufflation on parallel conductance

American journal of physiology. Heart and circulatory physiology, 1998-08, Vol.275 (2), p.H653-H661

1998

Volltextzugriff (PDF)

Pharmacokinetics and safety of an oral ALK inhibitor, ASP3026, observed in a phase I dose escalation trial

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.2602-2602

2013

Volltextzugriff (PDF)

Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.2624-2624

2014

Volltextzugriff (PDF)

Abstract A165: Result of a phase 1 (dose-escalation stage), first-in-human study of ASP5878, an oral FGFR inhibitor, in patients with advanced solid tumors

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.A165-A165

2015

Volltextzugriff (PDF)

Stereoselective preparation of N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3- (2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide, a potent and orally active dual neurokinin NK(1)/NK(2) receptor antagonist

Journal of medicinal chemistry, 2003-07, Vol.46 (16), p.3508-3513

2003

Volltextzugriff (PDF)

Stereoselective Preparation of N -[( R,R )-( E )-1-(3,4-dichlorobenzyl)-3- (2-oxoazepan-3-yl)carbamoyl]allyl- N -methyl-3,5-bis(trifluoromethyl)benzamide, a Potent and Orally Active Dual Neurokinin NK 1 /NK 2 Receptor Antagonist

Journal of medicinal chemistry, 2003-07, Vol.46 (16), p.3508-3513

2003

Volltextzugriff (PDF)

Sense and antisense: Therapeutic potential of oligonucleotides and interference RNA in asthma and allergic disorders: Cutting edge issues in allergy

Clinical reviews in allergy & immunology, 2004, Vol.27 (3), p.207-217

2004

Volltextzugriff (PDF)

1 – 25 von 711

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(384)
Mit Volltextzugriff
(595)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Ebook Central Perpetual and DDA
(245)
eBooks on EBSCOhost
(245)
De Gruyter eBooks
(191)
EZB Electronic Journals Library
(185)
MEDLINE
(153)
Ingenta
(139)
Journals@Ovid
(134)
Publisher or Other Site
(121)
JSTOR Complete Journals
(106)
Elsevier ScienceDirect Journals Complete
(69)
Oxford Journals
(58)
IngentaConnect Journals
(53)
Wiley Online Library - AutoHoldings Journals
(47)
Elsevier ScienceDirect Journals Complete
(44)
Wiley Online Library All Obooks
(42)
Oxford University Press Books All Titles
(37)
Psychology and Behavioral Sciences Collection
(34)
Wiley Online Library Full Collection 2018
(26)
Nexis Uni
(26)
SAGE Complete
(24)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Pazopanib Efficacy in Renal Cell Carcinoma: Evidence for Predictive Genetic Markers in Angiogenesis-Related and Exposure-Related Genes

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors

First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer

A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies

BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer

Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors

A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors

A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors

Stereoselective Preparation of N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3- (2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide, a Potent and Orally Active Dual Neurokinin NK1/NK2 Receptor Antagonist

At Liberty to Die: The Battle for Death with Dignity in America

Sense and antisense: therapeutic potential of oligonucleotides and interference RNA in asthma and allergic disorders

Effect of P‐glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine

The Supreme Court in the Intimate Lives of Americans: Birth, Sex, Marriage, Childrearing, and Death

Dual neurokinin NK1/NK2 antagonists : N-[(R, R)-(E)-1-arylmethyl-3-(2-oxo-azepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis( trifluoromethyl)benzamides and 3-[N'-3,5-bis(trifluoromethyl)benzoyl-N-arylmethyl-N'-methylhydrazino]-N-[(R)-2- oxo-azepan-3-yl]propionamides

Biphenyl derivatives as novel dual NK1/NK2-Receptor antagonists

Prevention of vascular nitroglycerin tolerance by inhibition of protein kinase C

Clinical potential of respirable antisense oligonucleotides (RASONs) in asthma

Simultaneous LV and RV volumes by conductance catheter: effects of lung insufflation on parallel conductance

Pharmacokinetics and safety of an oral ALK inhibitor, ASP3026, observed in a phase I dose escalation trial

Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a “fast follower” phase 1 trial design

Abstract A165: Result of a phase 1 (dose-escalation stage), first-in-human study of ASP5878, an oral FGFR inhibitor, in patients with advanced solid tumors

Stereoselective preparation of N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3- (2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide, a potent and orally active dual neurokinin NK(1)/NK(2) receptor antagonist

Stereoselective Preparation of N -[( R,R )-( E )-1-(3,4-dichlorobenzyl)-3- (2-oxoazepan-3-yl)carbamoyl]allyl- N -methyl-3,5-bis(trifluoromethyl)benzamide, a Potent and Orally Active Dual Neurokinin NK 1 /NK 2 Receptor Antagonist

Sense and antisense: Therapeutic potential of oligonucleotides and interference RNA in asthma and allergic disorders: Cutting edge issues in allergy

Suchergebnisse filtern